RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

2020/03/20 by Philippe Gautret, Jean-Christophe Lagier, Jean‐Christophe Lagier +19 · 4 voices · 39 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #COVID-19 Clinical Research Studies #Long-Term Effects of COVID-19 #Pharmacological Receptor Mechanisms and Effects

paper · doi:10.1016/j.ijantimicag.2020.105949

openalex publication_date 2020/03/20 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Cited by

• Why the article that led to the widespread use of hydroxychloroquine in COVID-19 should be retracted
• Raising concerns on questionable ethics approvals – a case study of 456 trials from the Institut Hospitalo-Universitaire Méditerranée Infection
• Hydroxychloroquine and COVID-19
• Open science saves lives: lessons from the COVID-19 pandemic
• Twitter and Facebook posts about COVID-19 are less likely to spread false and low-credibility content compared to other health topics
• Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics
• Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing Data
• The trinity of COVID-19: immunity, inflammation and intervention
• Understanding the Problem of “Hype”: Exaggeration, Values, and Trust in Science
• Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19
• Performance of AI Tools in Citing Retracted Literature : Content Analysis
• COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status
• Science communication and public trust in science
• Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing
• COVID-19 and Older Adults: What We Know. [europepmc]
• Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. [europepmc]
• Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? [europepmc]
• COVID-19 pathophysiology: A review. [europepmc]
• Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. [europepmc]
• The trinity of COVID-19: immunity, inflammation and intervention. [europepmc]
• COVID-19 diagnosis and management: a comprehensive review. [europepmc]
• Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. [europepmc]
• Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. [europepmc]
• Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. [europepmc]
• RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. [europepmc]
• Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. [europepmc]
• Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. [europepmc]
• Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. [europepmc]
• Immunology of COVID-19: Current State of the Science. [europepmc]
• SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. [europepmc]
• Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. [europepmc]
• Coronavirus Disease 2019-COVID-19. [europepmc]
• The cytokine storm and COVID-19. [europepmc]
• SARS-CoV-2 detection, viral load and infectivity over the course of an infection. [europepmc]
• COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. [europepmc]
• Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. [europepmc]
• Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. [europepmc]
• Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). [europepmc]
• No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. [europepmc]

Discussions

• Controversial COVID study that promoted unproven treatment retracted after four-year saga (a.k.a. the hydroxychloroquine study is finally retracted) [lemmy, 560 points, 45 comments]
• RETRACTED: Hydroxychloroquine and azithromycin as treatment of COVID-19 “Concerns about…article' adherence to Elsevier publishing ethics policies and appropriate conduct of research involving human p [bsky, 32 points, 1 comments]
• L’article mentionnant l’autorisation de CPP 20.02.28.99113 qui est rétracté est l’infame Gautret et al., source de souffrance évitables et d’une perte de temps dans la recherche mondiale sur le Covid- [bsky, 9 points, 2 comments]
• anyway, using citable items by WoS, citing articles by Pubmed, and the formula, Gautret et al. doi.org/10.1016/j.ij... accounted for 1.3 IF of the journal in 2021, 0.5 in 2022. Compared to 15 and 8 I [bsky, 0 points, 0 comments]